Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-10-05

Clinical Trial Update: Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects [Phase 1]

View source ↗

Summary

Phase 1 repeat-dose pharmacokinetics study of NRL-1 in epilepsy subjects has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NRL-1

Snippet

Sponsor: Neurelis, Inc. | Conditions: Acute Repetitive Seizures | Phase 1 | Status: COMPLETED | Results posted: 2021-10-05